Compositions and methods of modulating 15-PGDH activity
AssigneesCase Western Reserve University, Board of Regents, The University of Texas System, University of Kentucky Research Foundation
InventorsSanford Markowitz, James K. V. Willson, Bruce A. Posner, Joseph Ready, Yongyou Zhang, Hsin-Hsiung Tai, Monika Antczak, Stanton Gerson, KiBeom Bae, Sung Yeun Yang, Amar Desai
Life of this patent
Estimating the term…
Abstract
Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors and 15-PGDH activators described herein.
Claims10
A pharmaceutical composition comprising:
- a compound having the following formula:
- wherein n is 0-2;
- R1 is a C1-8 alkyl, which is linear, branched, or cyclic and which is unsubstituted or substituted;
- R6 is a thiazolyl and R7 is selected from the group consisting of a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, or heterocyclyl, and pharmaceutically acceptable salts thereof;
- and a pharmaceutically acceptable excipient.
A pharmaceutical composition consisting essentially of a compound having the formula:
- and pharmaceutically acceptable salts thereof.
A pharmaceutical composition comprising a compound having the formula:
- and pharmaceutically acceptable salts thereof wherein the composition includes greater than 99% by weight of the R(+) isomer of the compound and less than 1% by weight of the S(−) isomer of the compound.
A pharmaceutical composition comprising:
- a compound that inhibits 15-PGDH enzyme activity, the compound having the formula:
- wherein n is 0-2;
- R1 is a C1-8 alkyl, which is linear, branched, or cyclic and which is unsubstituted or substituted;
- R6 is a thiazolyl and R7 is selected from the group consisting of a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, or heterocyclyl, and pharmaceutically acceptable salts thereof;
- and a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.